CHF 4 million to improve cancer diagnostics

b-rayZ AG, a spin-off of the University Hospital Zurich (USZ), has closed an oversubscribed Series A financing round with leading investors in the Life Sciences and IT sector. The start-up aims to improve cancer diagnostics significantly with AI technology.

b-rayZ develops a unique and revolutionary AI-based platform supporting radiologists in the early detection of breast cancer. b-rayZ’s b-box system is already CE-marked and in commercial use in leading breast centers in Europe. With the funds, b ray-Z will expand sales in further European markets and reach FDA approval for the USA. In addition, b-rayZ plans to develop new products for gynecologists and radiologists based on its proprietary AI platform. The financing round was led by LifeCare Partners, Protagon AG and Convergence Partners and joined by the Eckenstein-Geigy-Foundation, the Swisspreneur association, and several private investors.

In 2020, more than 2.3 million women worldwide were diagnosed with breast cancer and 685,000 of them died from it. "Every 14 seconds, a woman is diagnosed with breast cancer somewhere in the world. Since 2008, the global incidence of breast cancer has increased by more than 20% and, regrettably, mortality has increased by 14%. With our platform, we can save thousands of lives through the earliest possible diagnosis and then subsequent support in the selection of personalized therapy," Cristina Rossi continues.

The b-rayZ system allows not only a quality-controlled mammography to significantly reduce late diagnosis but it also saves more than 25% time in the process and nearly 50% of the previous quality assurance costs. The effectiveness of b-rayZ’s deep-learning algorithms in the daily diagnostic procedures has been already clinically proven with more than 35,000 patients being successfully examined by leading radiologists.

(Press release / SK)
Photo: b-rayZ founding team: Prof. Dr. Cristina Rossi (l.), PD Dr. Alexander Ciritsis (m.), Prof. Dr. Dr. Andreas Boss